Beta-galactoside alpha-2,6-sialyltransferase 1
SIGMA/SAE0090 - ≥300 units/mg protein, ST6GAL1 human recombinant, expressed in HEK 293 cells
Synonym: Alpha 2,6-ST 1; B-cell antigen CD75; CMP-
Product Type: Chemical
The purity of Beta-galactoside alpha-2,6-sialyltransferase 1 human, recombinant (Cat. No. SAE0090) was assessed on SDS-PAGE stained with InstantBlue™ (Cat. No. ISB1L).
Activity Comparison of ST6GAL1 ST6GAL1 human recombinant ability to transfer sialic acid from CMP-NANA to asialofetuin was found to be significantly higher than the activity of ST6GAL1 from Photobacterium damsela. Purple: ST6GAL1 human recombinant, expressed in HEK 293 cells (Cat. No. SAE0090).Red: recombinant ST6GAL1 from Photobacterium damsela expressed in E. coli.
Transferring sialic acid from cytidine-monophosphate (CMP) onto Asialofetuin (Cat. No. A4781) has been studied using Beta-galactoside alpha-2,6-sialyltransferase 1 human, recombinant (ST6GAL1) (Cat. No. SAE0090) followed by LC/Q-TOF MS. Extracted ion chromatograms of common sialylated glycan fragments ions (MSE), m/z 292.1 (Neu5Ac + H)+ and m/z 657.2 (HexNAc + Hex + Neu5Ac + H)+ ,with and without ST6GAL1 are overlaid showing significantly higher levels of sialylated glycan fragments ions after enzyme activity.
| assay | ≥95% (SDS-PAGE) |
| description | The specific activity of ST6Gal I is measured by its ability to transfer sialic acid from CMP-NANA to asialofetuin. |
| form | lyophilized powder |
| recombinant | expressed in HEK 293 cells |
| shipped in | ambient |
| specific activity | ≥300 units/mg protein |
| storage temp. | −20°C |
| Biochem/physiol Actions: | ST6Gal I catalyzes the transfer of CMP-N-acetylneuraminate (CMP-sialic acid, CMP-NANA) to the β-D-galactosyl-1,4-N-acet Terminal sialylation has been shown to decrease Fcγ receptor binding and increase anti-inflammatory activity,3 as well as antibody-dependent cellular cytotoxicity in different studies by reduced binding of sialylated antibody towards FcγRIIIa.4-5 This recombinant ST6Gal I product can be used to study the mode of action of the enzyme, as well as its potential inhibitors. It can also be used as a glycoengineering tool to modify glycoproteins in vitro. CMP-N-acetylneuraminate (CMP-sialic acid, CMP-NANA) to the β-D-galactosyl-1,4-N-acet Sialic acids are distributed in a variety of glycolipids and glycoproteins. The sialic acid that is added to a galactose (Gal) can be bound either to the hydroxyl attached to carbon-3 of Gal to form an α-2,3 glycosidic linkage, or to the hydroxyl group attached to carbon-6 to form an α-2,6 glycosidic linkage. ST6Gal I generates a α-2,6 linkage of sialic acid on the non-reducing, terminal Galβ1 4GlcNAc residues of oligosaccharides and glycoconjugates. Terminal sialylation has been shown to decrease Fcγ receptor binding and increase anti-inflammatory activity, as well as antibody-dependent cellular cytotoxicity in different studies by reduced binding of sialylated antibody towards FcγRIIIa. |
| General description: | Recombinant human Beta-galactoside alpha-2,6-sialyltransfera |
| Other Notes: | One unit is defined as the amount of enzyme required to transfer 1.0 nanomole of sialic acid from CMP-NANA to asialofetuin per minute at pH 6.0, 37oC. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (SDS-PAGE) |
| activity | specific activity: ≥300 units/mg protein |
| Storage Temp. | −20°C |
| Enzyme Commission (EC) Number | 2.4.99.1  ( BRENDA  | IUBMB ) |
| UNSPSC | 12352202 |